Diabetes, Vol 43, Issue 2 329-336, Copyright © 1994 by American Diabetes Association

ARTICLES

Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis

TD O'Brien, AE Butler, PC Roche, KH Johnson and PC Butler
Endocrine Research Unit, Mayo Clinic, Rochester 55905.

Amyloid deposits that characteristically form in the pancreatic islets of patients with non-insulin-dependent diabetes mellitus (NIDDM) and in insulinomas are both derived from islet amyloid polypeptide (IAPP). Evidence from previous studies has suggested that deposition of IAPP-derived amyloid is related to inherent amyloidogenic sequences present within normal human IAPP, together with an increased production and local concentration of IAPP. However, whether the aggregation of IAPP to form amyloid fibrils is primarily an intra- or extracellular event is not clear. To address this question, we studied 20 human insulinomas by light and electron microscopy. By light microscopy, amyloid deposits were demonstrated in 13 of 20 (65%) human insulinomas. Furthermore, evaluation of Congo red-stained tumor sections showed small, globular or irregular, congophilic amyloid deposits within the cytoplasm of many tumor cells in 10 of 13 (77%) amyloid-containing insulinomas. Dense, punctate areas of IAPP immunoreactivity within tumor cells corresponded with the congophilic intracellular deposits. Ubiquitin immunoreactivity also was observed as punctate intracellular labeling and within large extracellular amyloid deposits. Among the 10 insulinomas available for electron microscopic evaluation, pathological IAPP-immunoreactive (immunogold) deposits were found in 3 of 5 insulinomas in which amyloid was demonstrated by light microscopy and in none of 5 tumors found negative for amyloid by light microscopy. Morphology of IAPP-immunoreactive deposits varied from those with the classical distinct 7- to 10-nm diameter nonbranching fibrils to those with distinct but faint fibrillarity to those without discernable fibrils.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. J. Meier, R. Kayed, C.-Y. Lin, T. Gurlo, L. Haataja, S. Jayasinghe, R. Langen, C. G. Glabe, and P. C. Butler Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1317 - E1324. [Abstract] [Full Text] [PDF]

				L. Marzban, C. J. Rhodes, D. F. Steiner, L. Haataja, P. A. Halban, and C. B. Verchere Impaired NH2-Terminal Processing of Human Proislet Amyloid Polypeptide by the Prohormone Convertase PC2 Leads to Amyloid Formation and Cell Death. Diabetes, August 1, 2006; 55(8): 2192 - 2201. [Abstract] [Full Text] [PDF]

				M. D. Lopez-Avalos, V. F. Duvivier-Kali, G. Xu, S. Bonner-Weir, A. Sharma, and G. C. Weir Evidence for a role of the ubiquitin-proteasome pathway in pancreatic islets. Diabetes, May 1, 2006; 55(5): 1223 - 1231. [Abstract] [Full Text] [PDF]

				C.-Y. Lin, T. Gurlo, L. Haataja, W. A. Hsueh, and P. C. Butler Activation of Peroxisome Proliferator-Activated Receptor-{gamma} by Rosiglitazone Protects Human Islet Cells against Human Islet Amyloid Polypeptide Toxicity by a Phosphatidylinositol 3'-Kinase-Dependent Pathway J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6678 - 6686. [Abstract] [Full Text] [PDF]

				J. F. Paulsson and G. T. Westermark Aberrant Processing of Human Proislet Amyloid Polypeptide Results in Increased Amyloid Formation Diabetes, July 1, 2005; 54(7): 2117 - 2125. [Abstract] [Full Text] [PDF]

				S. Andrikopoulos, R. L. Hull, C. B. Verchere, F. Wang, S. M. Wilbur, T. N. Wight, L. Marzban, and S. E. Kahn Extended life span is associated with insulin resistance in a transgenic mouse model of insulinoma secreting human islet amyloid polypeptide Am J Physiol Endocrinol Metab, March 1, 2004; 286(3): E418 - E424. [Abstract] [Full Text]

				J. Janson, T. Laedtke, J. E. Parisi, P. O'Brien, R. C. Petersen, and P. C. Butler Increased Risk of Type 2 Diabetes in Alzheimer Disease Diabetes, February 1, 2004; 53(2): 474 - 481. [Abstract] [Full Text]

				H.-L. Zhao, F. M.M. Lai, P. C.Y. Tong, D.-R. Zhong, D. Yang, B. Tomlinson, and J. C.N. Chan Prevalence and Clinicopathological Characteristics of Islet Amyloid in Chinese Patients With Type 2 Diabetes Diabetes, November 1, 2003; 52(11): 2759 - 2766. [Abstract] [Full Text] [PDF]

				A. E. Butler, J. Janson, W. C. Soeller, and P. C. Butler Increased {beta}-Cell Apoptosis Prevents Adaptive Increase in {beta}-Cell Mass in Mouse Model of Type 2 Diabetes: Evidence for Role of Islet Amyloid Formation Rather Than Direct Action of Amyloid Diabetes, September 1, 2003; 52(9): 2304 - 2314. [Abstract] [Full Text] [PDF]

				R. A. Ritzel and P. C. Butler Replication Increases {beta}-Cell Vulnerability to Human Islet Amyloid Polypeptide-Induced Apoptosis Diabetes, July 1, 2003; 52(7): 1701 - 1708. [Abstract] [Full Text] [PDF]

				A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler {beta}-Cell Deficit and Increased {beta}-Cell Apoptosis in Humans With Type 2 Diabetes Diabetes, January 1, 2003; 52(1): 102 - 110. [Abstract] [Full Text] [PDF]

				M. Hoenig, G. Hall, D. Ferguson, K. Jordan, M. Henson, K. Johnson, and T. O'Brien A Feline Model of Experimentally Induced Islet Amyloidosis Am. J. Pathol., December 1, 2000; 157(6): 2143 - 2150. [Abstract] [Full Text] [PDF]

				H. J. Hiddinga and N. L. Eberhardt Intracellular Amyloidogenesis by Human Islet Amyloid Polypeptide Induces Apoptosis in COS-1 Cells Am. J. Pathol., April 1, 1999; 154(4): 1077 - 1088. [Abstract] [Full Text] [PDF]

				P. J. Tienari, N. Ida, E. Ikonen, M. Simons, A. Weidemann, G. Multhaup, C. L. Masters, C. G. Dotti, and K. Beyreuther Intracellular and secreted Alzheimer beta -amyloid species are generated by distinct mechanisms in cultured hippocampal neurons PNAS, April 15, 1997; 94(8): 4125 - 4130. [Abstract] [Full Text] [PDF]